Affiliation:
1. SJ LTD
2. TESTGEN LTD
3. TESTGEN LTD; Samara State Medical University
Abstract
Colorectal cancer is one of the most frequently diagnosed malignant tumors in men and women, which is a highly heterogeneous group of neoplasms consisting of subclasses with different molecular and clinical characteristics, and, as a consequence, patients with different types of tumors require different treatment protocols. Among the predictive factors of treatment response in patients with metastatic colorectal cancer, the most studied are the genes of the RAS family (KRAS, NRAS). Determination of RAS status is the first step in individual selection of drug therapy in patients with metastatic colorectal cancer. Patients with certain mutations in KRAS and NRAS genes are resistant to anti-EGFR therapy and have a lower median survival than WT (wild type) genotypes, indicating a negative prognosis in the presence of mutations.
Publisher
Reaviz Medical University
Reference40 articles.
1. Davydov M.I., Aksel E.M. Statistics of malignant neoplasms in Russia and the CIS countries in 2012. Vestnik RONC im. N.N. Blokhina = Bulletin of N.N. Blokhin Russian Cancer Research Center. 2014 (In Russ).
2. Pancione M., Remo A., Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int. 2012;2012:509348. https://doi.org/10.1155/2012/509348
3. Bishehsari F., Mahdavinia M., Vacca M. et al. Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol. 2014; 20(20):6055-6072. https://doi.org/10.3748/wjg.v20.i20.6055
4. Kondo Y., Issa J.P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):29-39. https://doi.org/10.1023/a:1025806911782
5. Cohen R., Pudlarz T., Delattre J.F. et al. Molecular targets for the treatment of metastatic colorectal cancer. Cancers (Basel). 2020;12(9):2350. https://doi.org/10.3390/cancers12092350